文献速递心律失常

CPVT与短QT综合征基因有效性评估

Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death.
PubMed 文献 · Eur Heart J · 2022-01-01

该研究采用ClinGen基因 curation框架,由三个团队独立评估11个CPVT和9个SQTS相关基因的证据,并经通道病专家组最终分类。结果显示7个CPVT基因和4个SQTS基因有有效致病证据,应纳入基因检测 panel,而部分争议基因表型不典型或变异人群频率过高。

要点

  • 7个CPVT基因(RYR2、CALM1-3、CASQ2、TRDN、TECRL)有明确至中等致病证据。
  • SQTS仅KCNH2为明确致病基因,KCNQ1、KCNJ2、SLC4A3为强至中等证据。
  • KCNJ2、PKP2、SCN5A报告表型非典型CPVT,ANK2变异人群频率过高。

核心结论

  • 7个CPVT基因和4个SQTS基因有有效致病证据,应纳入基因检测panel。
  • 与CPVT/SQTS临床特征相似的疾病相关基因可用于鉴别诊断。

研究设计与样本

  • 三个团队独立使用ClinGen基因 curation框架评估所有已发表证据。
  • 评估11个CPVT和9个SQTS相关基因,由通道病专家组最终分类。

主要发现

  • CPVT:7个基因有明确至中等证据,常染色体显性(RYR2、CALM1、CALM2、CALM3)或隐性(CASQ2、TRDN、TECRL)遗传。
  • CPVT争议基因:KCNJ2、PKP2、SCN5A报告表型非典型CPVT;ANK2变异人群频率过高。
  • SQTS:仅KCNH2为明确致病,KCNQ1、KCNJ2、SLC4A3为强至中等证据。
  • SQTS基因多数遗传证据来自极少数变异(KCNJ2五个、KCNH2两个、KCNQ1/SLC4A3各一个)。

临床怎么用

  • 基因检测panel应包含7个CPVT基因和4个SQTS基因。
  • 对CPVT/SQTS疑似患者,可考虑检测表型相似疾病相关基因以鉴别诊断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Catecholaminergic polymorphic ventricular tachycardia (CPVT) and short QT syndrome (SQTS) are inherited arrhythmogenic disorders that can cause sudden death. Numerous genes have been reported to cause these conditions, but evidence supporting these gene-disease relationships varies considerably. To ensure appropriate utilization of genetic information for CPVT and SQTS patients, we applied an evidence-based reappraisal of previously reported genes. METHODS AND RESULTS: Three teams independently curated all published evidence for 11 CPVT and 9 SQTS implicated genes using the ClinGen gene curation framework. The results were reviewed by a Channelopathy Expert Panel who provided the final classifications. Seven genes had definitive to moderate evidence for disease causation in CPVT, with either autosomal dominant (RYR2, CALM1, CALM2, CALM3) or autosomal recessive (CASQ2, TRDN, TECRL) inheritance. Three of the four disputed genes for CPVT (KCNJ2, PKP2, SCN5A) were deemed by the Expert Panel to be reported for phenotypes that were not representative of CPVT, while reported variants in a fourth gene (ANK2) were too common in the population to be disease-causing. For SQTS, only one gene (KCNH2) was classified as definitive, with three others (KCNQ1, KCNJ2, SLC4A3) having strong to moderate evidence. The majority of genetic evidence for SQTS genes was derived from very few variants (five in KCNJ2, two in KCNH2, one in KCNQ1/SLC4A3). CONCLUSIONS: Seven CPVT and four SQTS genes have valid evidence for disease causation and should be included in genetic testing panels. Additional genes associated with conditions that may mimic clinical features of CPVT/SQTS have potential utility for differential diagnosis.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Walsh R, Adler A, Amin AS, et al. Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death. Eur Heart J. 2022. PMID: 34557911. doi:10.1093/eurheartj/ehab687

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。